Significant Gaps in Vaccine Uptake, Trust for US Adults
An NFID initiative provided evidence-based guidance on influenza, COVID-19, and RSV during the 2025-2026 season.
Tag: vaccine pneumococcal
All
Latest
Significant Gaps in Vaccine Uptake, Trust for US Adults
An NFID initiative provided evidence-based guidance on influenza, COVID-19, and RSV during the 2025-2026 season.
Read More
Pneumococcal Pneumonia Vaccination for High-Risk Adults
A campaign from the American Lung Association urges vaccination for pneumococcal pneumonia, which hospitalizes 225,000 Americans each year.
Read More
Court Blocks HHS Revisions to Child Vaccine Schedule
A US district court blocked HHS Secretary Robert Kennedy Jr’s recent moves to revise the federal childhood vaccine schedule and overhaul of the CDC’s vaccine advisory board, according to multiple media reports including Reuters.
Read More
AAP Issues Immunization Schedule for 2026
The 2026 AAP recommendations remain largely unchanged from 2025 but differ from the CDC’s new immunization schedule.
Read More
AAP Opposes HHS Changes to Childhood Immunization Schedule
AAP president Andrew D. Racine is raising alarms over the federal government’s removal of several vaccinations from its Childhood Immunization Schedule.
Read More
CDC/HHS Remove Vaccines from Childhood Immunization Schedule
The CDC and HHS reduced the federally recommended childhood immunization schedule from 17 to 11 vaccinations, removing shots for seasonal flu and other infectious diseases.
Read More
ESC Advocates Vaccination for Cardiovascular Prevention
A new ESC Clinical Consensus Statement reports on the beneficial effects of vaccines in reducing cardiovascular events following various viral and bacterial infections, particularly in at-risk patient groups.
Read More
CDC: ‘The Decision to Vaccinate Is a Personal One’
A recent CDC statement may signal a shift in the agency’s longstanding practice of advocating vaccinations for infectious diseases like measles.
Read More
Countering the Next Phase of Anti-vaccine Activism
Scientist offer strategies to address anti-vaccine sentiment in the US, including actively countering health disinformation.
Read More
American Confidence in RSV Vaccines Rises, Survey Finds
A new Annenberg Public Policy Center survey reveals evolving public attitudes toward vaccines—including RSV, flu, COVID-19, and MMR—in the United States.
Read More
CDC Lowers Age for Pneumococcal Vaccination from 65 to 50
Lowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.
Read More
ACP Urges Adults to Get Recommended Vaccinations
The American College of Physicians is advising adults to get all recommended vaccines to protect against preventable diseases and reduce the spread of infection.
Read More
FDA Approves Merck’s Pneumococcal Vaccine for Adults
The vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older.
Read More
FDA Grants Priority Review to Merck’s Pneumococcal Conjugate Vaccine for Adults
The FDA accepted for priority review a new Biologics License Application for V116, Merck’s investigational 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
Read More
ATS Broadens Vaccine Push with Partnership from Five More Health Systems
The health systems will prioritize improving vaccine rates among high-risk adults with lung disease across different populations.
Read More
Common Vaccines May Shield Against Alzheimer’s Disease
A year after discovering that flu vaccines decrease the risk of Alzheimer’s disease by 40%, the same research team found that several other common vaccines also provide protective benefits.
Read More
FDA Approves 20-valent Pneumococcal Vaccine for Infants and Children
The vaccine builds on the company’s previously approved vaccine by including seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.
Read More
FDA Approves Vaxneuvance Pneumococcal Vaccine for Infants, Children
The FDA has expanded the approval for Merck’s Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
Read More
Pfizer COVID-19 and Pneumococcal Vaccines Safe to Co-administer
Pfizer’s Prevnar 20 pneumococcal vaccine can be safely co-administered with the Pfizer-BioNTech COVID-19 vaccine, according to a Phase 3 study.
Read More
Merck VaxNeuvance Pneumococcal Vaccine Approved in EU
The European Commission approved Merck’s VaxNeuvance (Pneumococcal 15-valent Conjugate Vaccine) for prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Read More
FDA Approves Merck Capvaxive Pneumococcal Vaccine
The US FDA has approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine).
Read More
FDA Approves Prevnar 20 Pneumoccocal Vaccine
The US FDA has approved Pfizer’s Prevnar 20 Pneumococcal 20-valent Conjugate Vaccine for the prevention of invasive disease and pneumonia in adults age 18 and older.
Read More
Positive Data for Merck’s Pneumococcal Conjugate Vaccine Candidate
Two Phase 3 studies of Merck’s investigational 15-valent pneumococcal conjugate vaccine met their primary immunogenicity objectives.
Read More
A Study of The Psychology of Anti-Vaxxers
People with vaccine skepticism overestimate the likelihood of all kinds of negative events, especially those that are rare, according to a new study published in the journal Vaccine.
Read More